Improving the relative dose intensity of systemic chemotherapy in a community-based outpatient cancer center

Journal of Oncology Practice

Volumn 9, Issue 5, 2013, Pages

  Vavra, Kari L ^a   Saadeh, Claire E ^a   Rosen, Alisha L ^a   Uptigrove, Christine E ^a   Srkalovic, Gordan ^a  

^a FERRIS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; COLON CANCER; COMMUNITY CARE; CONTROLLED STUDY; DRUG DOSE; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEMATOLOGIC DISEASE; HUMAN; INTERDISCIPLINARY EDUCATION; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; METASTASIS; NONHODGKIN LYMPHOMA; OVARY CANCER; PATIENT COMPLIANCE; RELATIVE DOSE INTENSITY; REVIEW; RISK ASSESSMENT; TOTAL QUALITY MANAGEMENT; TREATMENT REFUSAL;

ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; CHEMOTHERAPY, ADJUVANT; COMMUNITY HEALTH CENTERS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; DRUG UTILIZATION REVIEW; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS; OUTPATIENTS; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84892595859     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2012.000810     Document Type: Review

References (22)

1. DeVita VT, Chu E: Principles of medical oncology, in DeVita VT, Lawrence TS, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 2008, pp 340-342
2. Foote M: The importance of planned dose of chemotherapy on time: Do we need to change our clinical practice? Oncologist 3: 365-368, 1998 (Pubitemid 28485579)
3. Lyman GH: Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 7: 99-108, 2009
4. Hryniuk VM: The importance of dose intensity in the outcome of chemotherapy, in DeVita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1988, pp 121-142
5. Link BK, Budd GT, Scott S, et al: Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: Current patterns of care. Cancer 92:1354- 1367, 2001 (Pubitemid 32947818)
6. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 21: 4524-4531, 2003 (Pubitemid 46594022)
7. Lyman GH, Dale DC, Friedberg J, et al: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study. J Clin Oncol 22: 4302-4311, 2004 (Pubitemid 41185151)
8. Norton L: Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6: 30-35, 2001 (suppl 3) (Pubitemid 32423184)
9. Picozzi VJ, Pohlman BL, Morrison VA, et al: Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology 15: 1296-1306, 2001 (Pubitemid 33739241)
10. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431-1439, 2003 (Pubitemid 46594092)
11. Kwak LW, Halpern J, Olshen RA, et al: Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 8: 963-977, 1990 (Pubitemid 20200184)
12. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 332: 901-906, 1995
13. Bonadonna G, Moliterni A, Zambetti M, et al: 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ 330:217, 2005
14. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24: 3187-3205, 2006 (Pubitemid 46638957)
15. Lenhart C: Relative dose intensity: Improving cancer treatment and outcomes. Oncol Nurs Forum 32: 757-764, 2005
16. Amgen: Increasing awareness of relative dose intensity in an evidence-based practice, 9/08 update. http://www.onsedge.com/pdf/amgenEBP.pdf
17. NearSpace: Please note: The RDI Calculator is no longer available. For technical support on existing installations, please contact NearSpace, Inc. at (888) 827-4146. http://www.nearspace.com/medical-calculator/rdi/)
18. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Myeloid growth factors V. 1.2010. http://jhasioncology.com/fn2010/ eresourcecenter/pdfs/NCCN%20myeloid-growth%20factor%20guidelines.%20v1. 2010.pdf
19. NCSS Statistical Software: NCSS and PASS. http://www.ncss.com/
20. Uptigrove C, Vavra K, Saadeh C, et al: Relative dose intensity of systemic chemotherapy in an outpatient cancer center. Acta Med Acad 39: 144-149, 2010
21. Shayne M, Crawford J, Dale DC, et al: Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 100: 255-262, 2006 (Pubitemid 44707919)
22. Weycker D, Barron R, Edelsberg J, et al: Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat 133: 301-310, 2012